[Clinical evaluation of modified cyclazocine neuroleptanesthesia--a report by a Group on the Study of Modified Cyclazocine NLA].
Explore the source record for details and available documents.
Adult↗
SEARCH · Search PubMed
Results for “Cyclazocine”
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Affinity of the enantiomers of alpha- and beta-cyclazocine for binding to the phencyclidine and mu opioid receptors.
The enantiomers in the alpha and beta series of cyclazocine were evaluated for their ability to bind to phencyclidine (PCP) and mu-opioid receptors in order to determine their receptor selectivity. The affinity of (-)-beta-cyclazocine for the PCP receptor was 1.5 greater than PCP itself. In contrast, (-)-alpha-cyclazocine, (+)-alpha-cyclazocine, and (+)-beta-cyclazocine were 3-, 5- and 138-fold less potent than PCP, respectively. Scatchard analysis of saturable binding of [3H]Tyr-D-Ala-Gly-N-MePhe-Gly-ol (DAMGO) also exhibited a homogeneous population of binding sites with an apparent KD of 1.9 nM and an estimated Bmax of 117 pM. [3H]Tyr-D-Ala-Gly-N-MePhe-Gly-ol (DAMGO) binding studies revealed that (-)-alpha-cyclazocine (KD = 0.48 nM) was 31-, 1020- and 12,600-fold more potent than (-)-beta-cyclazocine, (+)-alpha-cyclazocine and (+)-beta-cyclazocine, respectively, for binding to the mu-opioid receptor. These data show that, although (-)-beta-cyclazocine is a potent PCP receptor ligand consistent with its potent PCP-like discriminative stimulus effects, it shows little selectivity for PCP receptors since it also potently displaces mu-opioid binding. However, these cyclazocine isomers, due to their extraordinary degree of stereoselectivity, may be useful in characterizing the structural requirements for benzomorphans having activity at the PCP receptor.
Animals↗
The effects of (-)- and (+)-beta-cyclazocine on NMDA-evoked responses and NMDA-mediated cell damage in cultured rat hippocampal neurons.
Microspectrofluorimetric measurements of excitatory amino acid-evoked rises in intracellular free calcium concentration ([Ca2+]i), electrophysiological measurements of currents through single NMDA receptor-operated ion channels and estimates of cellular viability following NMDA challenge were employed to examine the interactions of (-)- and (+)-beta-cyclazocine with the NMDA receptor-channel complex in cultured rat hippocampal neurons. Rises in [Ca2+]i evoked by NMDA, but not those evoked by kainate, AMPA or 50 mM K+, were reduced by (-)-beta-cyclazocine in a concentration- and use-dependent manner with an estimated IC50 value of 272 nM. In outside-out patches, (-)-beta-cyclazocine did not change the magnitudes of unitary NMDA-evoked currents but diminished both the frequency of channel openings and their mean open time. The IC50 for (-)-beta-cyclazocine against NMDA channel open state probability was estimated at 84 nM. The actions of (-)-beta-cyclazocine were consistent with a voltage-dependent open channel block of the NMDA channel with a blocking rate constant of 7.03.10(7) M-1.s-1 at -40 mV. Neurons exposed to a high concentration of NMDA in vitro were protected from death by 1 and 10 microM (-)-beta-cyclazocine. In all of the above assays, (+)-beta-cyclazocine was considerably less potent an NMDA antagonist and neuroprotective agent than (-)-beta-cyclazocine; the IC50 for (+)-beta-cyclazocine against channel open state probability was estimated at 14 microM. The results demonstrate that (-)-beta-cyclazocine is a potent and selective inhibitor of NMDA-evoked responses in cultured rat hippocampal neurons and an effective neuroprotective agent in vitro.
Animals↗
The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.
A series of morphine-like and nalorphine-like drugs were studied in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. In the nondependent dog, three profiles of activity were found which could be utilized to distinguish between morphine, WIN 35, 197-2 and cyclazocine. Propiram, a prototypic partial agonist of the morphine type, produced morphine-like effects in nondependent dogs and both precipitated and suppressed abstinence in cyclazocine-dependent dogs as was needed to precipitate abstinence in morphine-dependent dogs. WIN 35, 197-2, a strong agonist in the guinea-pig ileum which has been shown to be resistant to antagonism by naloxone, neither precipitated nor suppressed morphine abstinence but suppressed cyclazocine abstinence. In the nondependent dog, it depressed the flexor reflex but not skin twitch reflex. Cyclazocine altered reflex activity much like WIN 35, 197-2 but produced tachycardia, tachypnea, mydriasis and canine delirum. The morphine and cyclazocine precipitated and withdrawal abstinence syndromes were qualitatively different. Twenty times as much naltrexone was needed to precipitate abstinence in morphine-dependent dogs. Nalorphine both precipitated and suppressed cyclazocine abstinence and appeared to be a partial agonist of the nalorphine-type. Morphine suppressed the cyclazocine abstinence syndrome. Cross-tolerance was not observed in ketocyclazocine-dependent dogs. These data are consistent with the hypothesis that there are strong and partial agonists of the mu and kappa types, and further, that physical dependence on morphine and cyclazocine is mediated through different receptors. WIN 35, 197-2 appears to be a pure strong agonist of the kappa type. Cyclazocine is a mu antagonist and mixed kappa and sigma agonist.
Animals↗
Discriminative stimulus properties of stereoisomers of cyclazocine in phencyclidine-trained squirrel monkeys.
Squirrel monkeys were trained to discriminate 0.16 mg/kg phencyclidine (PCP) from saline in a two-layer drug discrimination task on a fixed-ratio 32 schedule of food presentation. After reliable discriminative control of lever choice was established, dose-response determinations for generalization to the training dose of PCP were made with several doses of PCP, a racemic mixture of cyclazocine and the pure (+)- and (-)-isomers of cyclazocine. Only PCP and the (+)-isomer produced dose-dependent PCP-appropriate responding. Neither the racemic mixture nor (-)-cyclazocine produced over 25% PCP-appropriate responding at any of the doses tested. (+)-Cyclazocine was eight times less potent than PCP in producing drug-lever appropriate responding. (-)-Cyclazocine was about 30 times more potent than PCP and over 200 times more potent than (+)-cyclazocine in overall response rate suppression. The potency of the racemic mixture for response-rate suppression was consistent with an additive effect of the isomers. Neither the PCP-lever appropriate responding produced by (+)-cyclazocine nor the response-rate suppression produced by (-)-cyclazocine were antagonized by naloxone. Thus, racemic cyclazocine is composed of two isomers with differing behavioral effects. The (-)-isomer is more potent, and the (+)-isomer has more specificity for PCP-like effects.
Animals↗
Effects of cyclazocine on cocaine self-administration in rats.
Cyclazocine is a kappa-opioid receptor agonist and mu-opioid receptor antagonist that was studied in the 1960s as a potential treatment for heroin addicts. Based on the evidence that opioid mechanisms modulate the reinforcing effects of cocaine, it has been suggested that cyclazocine be reconsidered for use in treating cocaine dependence. In the present study, the effects of orally administered (+/-)-cyclazocine, (+)-cyclazocine and (-)-cyclazocine on intravenous cocaine self-administration were assessed in rats. (+/-)-Cyclazocine produced a dose-related (2-8 mg/kg) decrease in cocaine intake without affecting bar-press responding for water. Neither enantiomer significantly altered responding for either cocaine or water. The efficacy of orally administered (+/-)-cyclazocine on cocaine self-administration was comparable to that previously observed using the intraperitoneal route. Distinct actions of the enantiomers of cyclazocine that might contribute to the unique efficacy of the racemate are discussed. Although the mechanistic basis for the results are not entirely understood, the data suggest that (+/-)-cyclazocine should be considered as a potential treatment for cocaine dependence.
Administration, Oral↗
(+/-)Cyclazocine blocks the dopamine response to nicotine.
(+/-)Cyclazocine, synthesized by Archer in 1962, was originally tested as a treatment for heroin addiction. (+/-)Cyclazocine is a mu opioid antagonist and kappa opioid agonist, and because of these actions, would be expected to modulate dopamine release in the nucleus accumbens as well as the reinforcing effects of drugs of abuse. In a recent study (+/-)cyclazocine was reported to decrease cocaine self-administration in rats. The aim of the present study was to determine whether (+/-)cyclazocine would alter the dopaminergic effects of nicotine that are thought to mediate its rewarding effects. Using in vivo microdialysis in awake and freely moving rats, we investigated the effect of (+/-)cyclazocine (0.5 mg/kg, i.p.) on the acute dopamine response to nicotine (0.32 mg/kg, i.v. over a 5 min period, infused 30 min later) in the nucleus accumbens. (+/-)Cyclazocine significantly attenuated the increase in extracellular dopamine levels induced by the nicotine infusion and enhanced nicotine-induced increases in dopamine metabolites. (+/-)Cyclazocine alone did not significantly affect extracellular dopamine levels. However, both the (+) and (-) enantiomers of cyclazocine did alter basal dopamine levels and these effects made it difficult to assess their individual interactions with nicotine. The results suggest that the effects of both enantiomers contribute to the effects of the racemate; (+/-)cyclazocine may decrease the rewarding effect of nicotine and may be the prototype of a potentially novel treatment for smoking.
3,4-Dihydroxyphenylacetic Acid↗
Cyclazocine: comparison to hydromorphone and interaction with cocaine.
Kappa-opioid agonists produce neurobiological and behavioral effects opposite to those of cocaine and may be useful for the treatment of cocaine dependence. To evaluate the kappa- and mu-agonist effects of cyclazocine and to test whether cyclazocine pretreatment would attenuate the effects of cocaine, healthy, male and female, experienced opiate and cocaine users (n = 13) were enrolled in a two-phase study. In Phase 1, placebo, cyclazocine (0.2, 0.4 and 0.8 mg) and the mu-agonist hydromorphone (5 and 15 mg) were administered orally in six 4.5-hour sessions separated by at least 72 h. In Phase 2, cocaine (100 mg intranasal) was given 2 h after oral pretreatment with cyclazocine (0, 0.1, 0.2, 0.4, 0.8 and 0 mg, in that order) in each of six sessions conducted daily Monday to Friday and the following Monday. Physiological, subjective and behavioral measures were collected in each session. Nine participants completed Phase 1; eight completed Phase 2. Hydromorphone (15 mg) produced prototypic mu-agonist effects. Cyclazocine exhibited only modest kappa-like effects. Cyclazocine also had only modest, non-dose-related effects on response to cocaine. However, cocaine effects were consistently lower on the last administration (cyclazocine 0 mg pretreatment) following 4 days of cyclazocine pretreatment, compared to the first administration (0 mg pretreatment). This finding is unlikely to be fully attributable to cocaine tolerance and is not accounted for by pharmacokinetic changes; plasma concentrations of cocaine were not altered by cyclazocine. This study is suggestive but not strongly supportive for the use of kappa-opiate drugs to diminish acute effects of cocaine administration or for the use of these kappa agonists in drug abuse treatment applications.
Administration, Intranasal↗
[The role of serotonin in the behavioral changes induced in the rat by cyclazocine].
Cyclazocine is a benzomorphan derivative, considered as a mixed kappa and and sigma opioid receptor agonist. In experimental study with rats, cyclazocine is known to increase locomotor activity and to produce a bizarre behavioral syndrome including head swaying, backward walking, circling. The present study was undertaken to investigate the effects of various drugs modifying the serotoninergic neuronal systems, upon the locomotor activity and the abnormal behaviors induced by cyclazocine. Pretreatment with p-chlorophenylalanine (PCPA, 400 mg/kg, 72, 48, 24 hr) resulted in an inhibition of the three abnormal behaviors. Pretreatment with p-chloromethylamphetamine (PCMA, 15 mg/kg, 24 hr) antagonized head swaying, backward walking and markedly enhanced locomotor activity. In the contrary, pretreatment with PCMA (2.5 mg/kg, 15 min) resulted in enhanced abnormal behavioral responses to cyclazocine. L-tryptophan (50 mg/kg), 5-hydroxytryptophan (5-HTP, 50 mg/kg), or pargyline (50 mg/kg) inhibited abnormal behaviors and decreased locomotor activity. Serotonin antagonists with affinity fir both 5-HT1 and 5-HT2 receptors, metergoline (0.25-1 mg/kg), methysergide (1-5 mg/kg), amitriptyline (5-20 mg/kg), dl-propranolol (10-40 mg/kg) blocked head swaying and backward walking; only methysergide inhibited circling. All these drugs, except methysergide, markedly enhanced the cyclazocine-induced locomotor activity. In contrast, ketanserine (0.5-2 mg/kg) and pirenperone (0.05-0.2 mg/kg), serotonin antagonists with selective affinity for 5-HT2 receptors had no effects on the abnormal behaviors and locomotor activity. Taken together, these results suggest that a serotoninergic mediation is involved in the cyclazocine-induced abnormal behaviors, and that serotonin exerts an inhibitory control on the locomotor activity produced by the drug. These effects are probably associated with 5-HT1 receptors. Further experiments have shown that the drugs having being able to potentiate cyclazocine-induced locomotor activity, similarly potentiate the locomotor activity induced by levallorphan, morphinan derivative with cyclazocine-like properties but do not enhance the hyperactivity produced by a low dose of morphine. The data reported here, provide a contribution to the informations concerning the neuromediation of the effects of mixed kappa and sigma agonists and allow to compare the mechanism of action of cyclazocine with those of other psychotomimetic drugs.
Animals↗
Radioimmunoassay of cyclazocine and stereospecificity of antibody.
A new radioimmunoassay, using 3H-cyclazocine, rabbit antiserum and charcoal-dextran separation of bound and free cyclazocine, for the direct analysis of serum cyclazocine is described. This method, which is specific for cyclazocine and has a detection limit of ca. 25 pd/assay tube, was successful in determining the cyclazocine level in the sera of beagles intramuscularly injected with 3 or 10 microgram/kg cyclazocine. The drug half-life was 90 min; the apparent distribution volumes were 4.0 and 5.26 liter/kg, respectively. One of the antisera raised in rabbits immunized with dl-cyclazocine derivative-BSA conjugates was highly specific for l-cyclazocine.
Animals↗
Dissociation of the opioid and nonopioid effects of cyclazocine.
Lower IV doses of (dl)- and (l)-cyclazocine (0.05 and 0.50 mg/kg) in the rat produced opioid EEG and behavioral effects that were antagonized by naltrexone pretreatment. Higher IV doses of (dl)- and (l)-cyclazocine (1.00 and 2.00 mg/kg) produced initial "psychotomimetic-like" behavioral effects that were naltrexone-resistant, followed by the delayed emergence of opioid EEG and behavioral effects that were naltrexone-sensitive, (d)-Cyclazocine produced only "psychotomimetic-like" behavioral effects that were naltrexone-resistant. (dl)-Cyclazocine antagonized morphine-induced EEG and behavioral effects in naive rats. (l)-Cyclazocine precipitated withdrawal symptoms in morphine-dependent rats. In contrast, (d)-cyclazocine produced "psychotomimetic-like" effects, but no withdrawal symptoms. Thus, (dl)- and (l)-cyclazocine produced dose- and time-related opioid and nonopioid "psychotomimetic-like" effects, while (d)-cyclazocine produced only nonopioid "psychotomimetic-like" effects.
Animals↗
Phencyclidine-like discriminative stimulus effects of the stereoisomers of alpha- and beta-cyclazocine in rats.
Stereoisomers of alpha- and beta-cyclazocine were tested in rats trained to discriminate phencyclidine (PCP; 3.0 mg/kg i.p.) from saline in a two-lever, food-reinforced, drug-discrimination procedure. (+)-Alpha-cyclazocine and both (+)- and (-)-beta-cyclazocine substituted for PCP. Neither (+/-) nor (-)-alpha-cyclazocine substituted for PCP, although both compounds had potent, response-rate decreasing effects. When these two drugs were tested in combination with naltrexone, rate-suppressing effects were somewhat attenuated and both then resulted in substantial PCP-lever responding. Thus, PCP-like effects in the alpha series can be masked by opiate effects. (-)-Beta-cyclazocine was the most potent compound for mimicking the PCP discriminative stimulus, being 4 to 5 times more potent than PCP itself. The (+)-isomers in both the alpha and beta series were equipotent and over 10 times less potent than PCP. Thus, both stereoisomers of beta-cyclazocine have PCP-like discriminative stimulus properties and the (-)-isomer, in particular, is a very potent, selective, PCP-like compound. The stereoisomers of beta-cyclazocine have over a 50-fold potency difference for PCP-like effects, evidencing greater stereoselectivity for these actions than is commonly obtained with 6,7-benzomorphans. The stereoisomers of beta-cyclazocine should prove to be useful tools for studying the PCP/sigma-like effects of opioids.
Animals↗
Electrophysiological effects of cyclazocine on rat cerebellar Purkinje neurons: comparison with phencyclidine.
Cyclazocine is a benzomorphan which, in addition to more classical opiate properties, binds to the sigma opiate receptor site. Recently, it has been suggested that the sigma opiate receptor is identical to the binding site responsible for the actions of phencyclidine (PCP). Since the electrophysiological actions of PCP have already been demonstrated on rat cerebellar Purkinje neurons, the effects of cyclazocine were also studied in this system with the goal of comparing the electrophysiological effects of cyclazocine to those of PCP. Cyclazocine inhibited the spontaneous firing rates of Purkinje neurons. These responses were stereospecific and qualitatively appeared similar to the effects of PCP. Antipsychotic drugs, haloperidol and fluphenazine, partially antagonized the actions of cyclazocine, suggesting a catecholaminergic involvement similar to the mechanism proposed for PCP. Unlike PCP, the effects of cyclazocine were also partially reversed by the opiate antagonist, naloxone. Taken together, these results suggest that in the rat cerebellum cyclazocine may be interacting with at least two receptor mechanisms: a naloxone-sensitive opiate site, and a naloxone-insensitive site which might involve catecholaminergic mediation similar to the PCP mechanism of action. The naloxone-sensitive effects of cyclazocine, however, may be related to an interaction of the drug with kappa receptors rather than with the more classical mu or delta opiate mechanisms.
Action Potentials↗
NMDA receptor antagonist effects of the stereoisomers of beta-cyclazocine in rats, in vivo and in vitro.
(+)- and (-)-beta-cyclazocine were examined as NMDA receptor antagonists following bath application to rat cortical wedges in vitro and i.v. administration to rat spinal cord neurones in vivo. Both isomers were found to be selective NMDA antagonists with little effect on excitations evoked by quisqualate. In vitro, IC50 values for (-)- and (+)-beta-cyclazocine against responses to 40 microM NMDA were estimated at 0.51 and greater than 100 microM, respectively. In vivo, (-)-beta-cyclazocine 0.25 mg.kg-1 reduced NMDA-evoked excitations by 70%, an effect substantially greater than that produced by (+)-beta-cyclazocine 2.5 mg.kg-1. (-)-beta-cyclazocine is the most potent NMDA antagonist benzomorphan tested to date, being about twice as potent as (-)-alpha-cyclazocine in this respect. In addition, the separation in potency exhibited by the beta-cyclazocine enantiomers as NMDA antagonists is much greater than that reported previously for the stereoisomers of the alpha-series.
Animals↗
Cyclazocine disruption of operant behavior is antagonized by naloxone and metergoline.
Male Sprague-Dawley rats were trained to press a lever on a fixed ratio-40 (FR-40) schedule for food reinforcement. Doses ranging from 0.5 to 16 mg/kg of the mixed narcotic agonist-antagonist cyclazocine (30-min pretreatment) resulted in a dose-dependent decrease in the number of reinforcements obtained and a reciprocal increase in "pausing" (IRT's greater than 10 sec). A 5-min pretreatment with 4 mg/kg of the narcotic antagonist naloxone attenuated the cyclazocine disruption. The 5-HT antagonist metergoline (1 mg/kg; 180-min pretreatment) also blocked cyclazocine effects to approximately the same degree as did naloxone. However, the shift of the dose response pattern of cyclazocine was not parallel for either antagonist. A greater degree of attenuation of the cyclazocine effects was observed when naloxone (4 mg/kg) and metergoline (0.1 mg/kg) were given together, indicating that cyclazocine disruption may be antagonized by either a narcotic antagonist or a 5-HT antagonist, and that these antagonists may operate synergistically. Thus, the behavioral effects of cyclazocine may relate to both opioid and serotonergic components.
Animals↗
Phencyclidine-like effect of cyclazocine on pentylentetrazol-induced seizures in laboratory animals.
The present work deals with an EEG and behavioural study of the effect of cyclazocine against the convulsions due to pentylentetrazol (PTZ) in mice, rats and rabbits. In rats, cyclazocine, at the high doses (15-25 mg/kg) prevents the tonic motor convulsions and EEG epileptiform "grand mal" seizure induced by PTZ. In rabbits and mice, cyclazocine inhibits the tonic motor convulsions without modifying either the spike-frequency or the duration of the PTZ-induced EEG seizures. Naloxone, even at high doses, was not able to block the anticonvulsive effects of cyclazocine on PTZ-induced convulsions in the rat. The effects of cyclazocine were compared to those of phencyclidine. These results confirm the multiple behavioural effects of cyclazocine and support the idea that both cyclazocine and phencyclidine, may act on the PCP/sigma receptor identified in binding studies.
Animals↗
Cyclazocine-induced sleep disruptions in nondependent addicts.
After one adaptation night, the sleep of seven male nondependent opiate addicts was studied following intramuscular cyclazocine (0.125; 0.25; 0.50 mg/70 kg) or placebo at weekly intervals in a randomized double-blind crossover design. Drug effects were measured on sleep stages and several episodic phenomena. Cyclazocine caused dose-related increases in sleep latency, REMS latency, percent spindle sleep, and a marked increase over placebo in wakefulness, drowsiness, and shifts in sleep-waking states. Cyclazocine produced a dose-related decrease in all measures of delta sleep, and some measures of REMS, and a marked decrease below placebo of sleep efficiency and total REMS. All doses of cyclazocine caused sustained periods of waking with little muscle tension. Cyclazocine (0.5mg) consistently caused urination during periods of extended arousal; urination has not been seen after morphine or other opioids of the mu type. These studies indicate that cyclazocine has effects on human sleep which are in some ways similar and other ways dissimilar to morphine type analgesics. The results are consistent with the concept that cyclazocine is a mixed agonist-antagonist of the opioid type with agonist actions at the kappa receptor.
Adult↗
Effects of morphine, pentazocine and cyclazocine alone and in combination with naloxone on electric shock titration in the squirrel monkey.
The effects of morphine, pentazocine and cyclazocine were examined on a discrete-trial shock titration procedure. Monkeys received continuous shock during 15-sec shock periods. If the monkey did not respond during the shock period, shock remained on for 15 sec and then increased by one increment on the next 15-sec shock period. If five responses were made during the shock period, the shock was immediately terminated for 15 sec during which the chamber was dark (time out). After the 15-sec time out period, the shock resumed at the next lower intensity. Morphine, pentazocine and cyclazocine altered patterns and rates of responding similarly. At a low dose, pentazocine, cyclazocine and morphine decreased median shock levels and increased rates of responding in the presence and in the absence of shock (i.e., during time out). These effects were observed over a wider dose range with pentazocine and cyclazocine than with morphine; moreover, decreases in median shock level and increases in rates of responding in the absence of shock were of greater magnitude after pentazocine and cyclazocine than after morphine. At higher doses, morphine, pentazocine and cyclazocine increased median shock levels and decreased rates of responding in the absence of shock. Rates of responding in the presence of shock were either unchanged or decreased very slightly, suggesting that increases in the intensity at which shock is maintained under shock titration procedures is not necessarily due to decreases in rates of responding. In contrast, naloxone had very little behavioral effect when administered alone. The effects of morphine were antagonized by a dose of naloxone as low as 0.01 mg/kg, whereas higher doses of naloxone were required to antagonize the effects of pentazocine and cyclazocine.
Animals↗